News
03-15-2013, 04:22 AM
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.
More... (http://www.news-medical.net/news/20130315/Subcutaneous-administration-of-Herceptin-preferred-by-HER2-positive-breast-cancer-patients-over-IV.aspx)
More... (http://www.news-medical.net/news/20130315/Subcutaneous-administration-of-Herceptin-preferred-by-HER2-positive-breast-cancer-patients-over-IV.aspx)